Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer

OBJECTIVES: There is an urgent need for biomarkers that predict the survival outcome of patients diagnosed with metastatic pancreatic cancer, undergoing systemic chemotherapy. This study aimed to identify biomarkers associated with the survival of mPC patients treated with modified FOLFIRINOX (mFOLF...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Feifei, Liu, Chuan, Zhang, Weiguo, He, Sijia, Wang, Fan, Wang, Jingjue, Li, Qi, Zhou, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372918/
https://www.ncbi.nlm.nih.gov/pubmed/35965580
http://dx.doi.org/10.3389/fonc.2022.964115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372918/
https://www.ncbi.nlm.nih.gov/pubmed/35965580
http://dx.doi.org/10.3389/fonc.2022.964115

Ejemplares similares